Bessemer Group Inc. Sells 175,054 Shares of Thermo Fisher Scientific Inc. $TMO

Bessemer Group Inc. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 365,296 shares of the medical research company’s stock after selling 175,054 shares during the period. Bessemer Group Inc.’s holdings in Thermo Fisher Scientific were worth $211,672,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. New York Life Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 6.3% in the 4th quarter. New York Life Investment Management LLC now owns 54,492 shares of the medical research company’s stock worth $31,575,000 after acquiring an additional 3,252 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its position in Thermo Fisher Scientific by 13,800.0% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 417 shares of the medical research company’s stock valued at $243,000 after buying an additional 414 shares in the last quarter. Plancorp LLC increased its position in Thermo Fisher Scientific by 4.8% during the 4th quarter. Plancorp LLC now owns 1,120 shares of the medical research company’s stock valued at $649,000 after buying an additional 51 shares in the last quarter. Western Wealth Management LLC increased its position in Thermo Fisher Scientific by 32.6% during the 4th quarter. Western Wealth Management LLC now owns 4,494 shares of the medical research company’s stock valued at $2,604,000 after buying an additional 1,104 shares in the last quarter. Finally, Castle Rock Wealth Management LLC increased its position in Thermo Fisher Scientific by 2.1% during the 4th quarter. Castle Rock Wealth Management LLC now owns 3,667 shares of the medical research company’s stock valued at $2,091,000 after buying an additional 76 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $448.12 on Friday. The company has a market capitalization of $166.53 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.97 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The business’s fifty day moving average is $487.50 and its 200 day moving average is $542.85. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a $0.47 dividend. The ex-dividend date was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TMO. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Morgan Stanley reissued an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Finally, TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $616.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.